Last updated on April 2019

Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144


Brief description of study

This two-part, open-label extension and safety monitoring study will examine the safety and efficacy of continued etrolizumab treatment in patients with moderate to severely active Crohn's disease who were previously enrolled in the etrolizumab Phase III Study GA29144.

Clinical Study Identifier: NCT02403323

Contact Investigators or Research Sites near you

Start Over

Austin Hospital

Heidelberg, Australia
3.44miles
  Connect »

St Vincent's Hospital Melbourne

Fitzroy, Australia
4.05miles
  Connect »

Footscray Hospital

Footscray, Australia
7.06miles
  Connect »

The Alfred Hospital

Prahan, Australia
7.55miles
  Connect »

Emeritus Research

Malvern East, Australia
9.75miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.